Katchkovsky Svetlana, Meiri Reut, Lacham-Hartman Shiran, Orenstein Yaron, Levaot Noam, Papo Niv
Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Computer Science, Bar-Ilan University, Ramat Gan, Israel.
FEBS Lett. 2025 Feb;599(3):316-329. doi: 10.1002/1873-3468.15033. Epub 2024 Oct 23.
The interaction of sclerostin (Scl) with the low-density lipoprotein receptor-related protein 4 (LRP4) leads to a marked reduction in bone formation by inhibiting the Wnt/β-catenin pathway. To characterize the Scl-LRP4 binding interface, we sorted a combinatorial library of Scl variants and isolated variants with reduced affinity to LRP4. We identified Scl single-mutation variants enriched during the sorting process and verified their reduction in affinity toward LRP4-a reduction that was not a result of changes in the variants' secondary structure or stability. We found that Scl positions K75 (loop 1) and V136 (loop 3) are critical hotspots for binding to LRP4. Our findings establish the foundation for targeting these hotspots for developing novel therapeutic strategies to promote bone formation.
硬化蛋白(Scl)与低密度脂蛋白受体相关蛋白4(LRP4)相互作用,通过抑制Wnt/β-连环蛋白信号通路导致骨形成显著减少。为了表征Scl-LRP4结合界面,我们对Scl变体的组合文库进行了筛选,并分离出与LRP4亲和力降低的变体。我们鉴定了在筛选过程中富集的Scl单突变变体,并验证了它们对LRP4亲和力的降低——这种降低并非变体二级结构或稳定性变化的结果。我们发现Scl的K75位点(环1)和V136位点(环3)是与LRP4结合的关键热点。我们的研究结果为靶向这些热点开发促进骨形成的新型治疗策略奠定了基础。